AllSight
Companies · INBX · Biological Products, (No Diagnostic Substances)

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. (INBX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Inhibrx Biosciences, Inc. (INBX) stock — financials & valuation

Key numbers for Inhibrx Biosciences, Inc. (INBX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 55/100 — a percentile rank of Inhibrx Biosciences, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$1.4B
EV / EBITDA-11.8×
Return on equity260.8%
ROIC1273.6%
Revenue growth-100.0%
Debt / equity-3.3×
Dividend yield0.0%

Independent of the events above — derived from Inhibrx Biosciences, Inc.’s own financial statements and shown as context, never as advice.

Sep 28, 202650-patient expansion
Inhibrx adds 50 HPV+ patients to INBRX-106 trial, but evidence remains thin
Sep 8, 2026Above the bar
Inhibrx's INBRX-106 posts sharp HNSCC efficacy, but toxicity tempers the win
Aug 13, 2026Miss
More cash, more debt—and a narrow EPS miss beneath the biotech runway story
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact